Can Abbisko Therapeutics turn irpagratinib into the first approved FGFR4 therapy for hepatocellular carcinoma?
Abbisko Therapeutics won EMA orphan drug designation for irpagratinib in liver cancer. Read what this changes for FGFR4-targeted therapy.
Pharma & Biotech